TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Cover Story
Keywords: Jacques Bernier, targeted drugs, radiotherapy, clinical radiation oncology, .
This article has 0 comments
Jacques Bernier: keeping the faith
As a young medical school graduate in the ’70s, Jacques Bernier ignored warnings that drugs were about to replace radiotherapy. He believed that new technology would make it safer and more effective. Today, he has faith that synergies between radiotherapy and targeted drugs can bring further benefits – and he is determined to see Europe play a full part in the research effort.
» Marc Beishon
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck and Novartis.






